Moving from 25C room temperature to 4C refrigeration reduces reaction rates by roughly four-fold
Updated result (January 26, 2026): Roche announced full 48-week Phase II results from the CT388-103 trial (NCT06525935, n=469)
Clinical reviews 3 of peptide-based therapies suggest that, regarding the brain-gut axis, BPC 157 has neuroprotective and muscle-recovery properties
While other reviews have described the MACE risk reduction in the general population with T2DM [23, 24], non-T2DM [25], or both [26], the present study seeks to address the gap in the literature in providing a comprehensive meta-analysis on the number need to treat (NNT), efficacy and safety profile of GLP-1RA in reducing the risk of myocardial infarction (MI) and individual ASCVD constituents, namely non-fatal MI, unstable angina, coronary revascularization, and/or cardiovascular mortality